Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Piriya Luangwattananun"'
Autor:
Kwanpirom Suwanchiwasiri, Nattaporn Phanthaphol, Chalermchai Somboonpatarakun, Pornpimon Yuti, Jatuporn Sujjitjoon, Piriya Luangwattananun, John Maher, Pa‑thai Yenchitsomanus, Mutita Junking
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 175, Iss , Pp 116718- (2024)
Advanced cholangiocarcinoma (CCA) presents a clinical challenge due to limited treatment options, necessitating exploration of innovative therapeutic approaches. Bispecific T cell engager (BTE)-armed T cell therapy shows promise in hematological and
Externí odkaz:
https://doaj.org/article/da0cdd64944141d696bbc7413a2dbf6b
Autor:
Nisa Chuangchot, Pranisa Jamjuntra, Supaporn Yangngam, Piriya Luangwattananun, Suyanee Thongchot, Mutita Junking, Peti Thuwajit, Pa-Thai Yenchitsomanus, Chanitra Thuwajit
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Background Carcinoma-associated fibroblasts (CAFs) play a critical role in cancer progression and immune cell modulation. In this study, it was aimed to evaluate the roles of CAFs-derived IL-6 in doxorubicin (Dox) resistance and PD-L1-mediat
Externí odkaz:
https://doaj.org/article/eb48fc516ca1446f87621c44ad9aef9f
Autor:
Aussara Panya, Chutamas Thepmalee, Nunghathai Sawasdee, Sasithorn Saengmuang, Piriya Luangwattananun, Pa-thai Yenchitsomanus
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115827- (2023)
Precision immunotherapy, driven by genomic and bioinformatic advancements, has emerged as a promising and viable approach to combat cancer. Targeting neoantigens offers the advantage of specific immune responses with minimal off-tumor toxicity. In th
Externí odkaz:
https://doaj.org/article/0c846745b6384596951a9dfce143754c
Autor:
Pornpimon Yuti, Nunghathai Sawasdee, Krissada Natungnuy, Punchita Rujirachaivej, Piriya Luangwattananun, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 168, Iss , Pp 115691- (2023)
Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen (BCMA) has been approved for treating multiple myeloma (MM). Some clinical studies reported suboptimal outcomes, including reduced cytotoxicity of CAR-T cells and tumo
Externí odkaz:
https://doaj.org/article/54bf06e34f8e4a25b0e801bd657af1af
Autor:
Methi Wathikthinnakon, Piriya Luangwattananun, Nunghathai Sawasdee, Chutipa Chiawpanit, Vannajan Sanghiran Lee, Piyarat Nimmanpipug, Yingmanee Tragoolpua, Siriphorn Rotarayanont, Thanich Sangsuwannukul, Nattaporn Phanthaphol, Yupanun Wutti-in, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Mutita Junking, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Aussara Panya
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Cholangiocarcinoma (CCA) is a lethal cancer with rapid progression and poor survival. Novel and more effective therapies than those currently available are, therefore, urgently needed. Our research group previously reported the combination o
Externí odkaz:
https://doaj.org/article/c30fc759386341b294deabee9dff6509
Autor:
Chanitra Thuwajit, Pa-thai Yenchitsomanus, Peti Thuwajit, Pornchai O-Charoenrat, Doonyapat Sa-nguanraksa, Nisa Chuangchot, Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Niphat Jirapongwattana, Suyanee Thongchot
Dendritic cell (DC)–based T-cell activation is an alternative immunotherapy in breast cancer. The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) is overexpressed in triple-negative breast cancer (TNBC). The regu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58652b016c49d696f95ef278fe021b85
https://doi.org/10.1158/1535-7163.c.6543246.v1
https://doi.org/10.1158/1535-7163.c.6543246.v1
Autor:
Chanitra Thuwajit, Pa-thai Yenchitsomanus, Peti Thuwajit, Pornchai O-Charoenrat, Doonyapat Sa-nguanraksa, Nisa Chuangchot, Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Niphat Jirapongwattana, Suyanee Thongchot
Supplementary Figure from Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c782fdbc4598f95ed40a2189b8d92dd
https://doi.org/10.1158/1535-7163.22521987
https://doi.org/10.1158/1535-7163.22521987
Autor:
Chanitra Thuwajit, Pa-thai Yenchitsomanus, Peti Thuwajit, Pornchai O-Charoenrat, Doonyapat Sa-nguanraksa, Nisa Chuangchot, Wannasiri Chiraphapphaiboon, Piriya Luangwattananun, Niphat Jirapongwattana, Suyanee Thongchot
Supplementary Data from Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e6db8f5d1c82ccf1018438c12e8d8f
https://doi.org/10.1158/1535-7163.22521999
https://doi.org/10.1158/1535-7163.22521999
Autor:
WANNASIRI CHIRAPHAPPHAIBOON, PIRIYA LUANGWATTANANUN, AUSSARA PANYA, NIPHAT JIRAPONGWATTANA, PRIMANA PUNNAKITIKASHEM, THAWEESAK CHIEOCHANSIN, MUTITA JUNKING, PA-THAI YENCHITSOMANUS
Publikováno v:
Anticancer Research. 42:1785-1799
B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM
Autor:
Suyanee Thongchot, Niphat Jirapongwattana, Piriya Luangwattananun, Wannasiri Chiraphapphaiboon, Nisa Chuangchot, Doonyapat Sa-nguanraksa, Pornchai O-Charoenrat, Peti Thuwajit, Pa-thai Yenchitsomanus, Chanitra Thuwajit
Publikováno v:
Molecular Cancer Therapeutics. 21:727-739
Dendritic cell (DC)–based T-cell activation is an alternative immunotherapy in breast cancer. The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) is overexpressed in triple-negative breast cancer (TNBC). The regu